 Expected outcome: In the randomized clinical trial, a 50 reduction in the incidence of the composite outcome in the DHA group 4 placebo vs. 2 DHA is expected. Investigators expect to decrease defective deep placentation placental bed biopsies and defective placentation markers in DHA supplemented women. Investigators expect also to demonstrate that DHA enhances trophoblast migration and invasion in vitro and decreases production of inflammatory cytokines and anti-vasculogenic mediators. 